The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities Retatrutide May Redefine Multi-Receptor Therapeutics Triple agonism (GLP-1 + GIP + glucagon) isnt just about adding more receptors this distinct mechanism can boost energy expenditure, not just suppress appetite
This is an effective and possibly lifesaving detoxification treatment
Internal Linking Results Timeline Dosage Guide Diet Plan Final Verdict Semaglutide vs bariatric surgery is about risk vs speed
Sports-related injuries of the elbow
Hong Kong Research has found that Tesamorelin increases IGF-1 levels, supporting metabolism and tissue repair while having a shorter half-life than other GHRH analogs
The Gila Monster and the Billion-Dollar Molecule How a desert lizards venom, ignored by every major pharmaceutical company for nearly a decade, became the template for the worlds most-prescribed weight-loss drugs